The Dr. Geo Prostate Podcast

What is Triplet Therapy for Advanced Prostate Cancer with Dr. Rana McKay

May 12, 2025
Dr. Rana McKay, an oncologist from UC San Diego Health with elite training from Harvard and Dana-Farber, unpacks the transformative triplet therapy for advanced prostate cancer. She explains how this innovative combo of ADT, ARPI, and chemotherapy outperforms traditional treatments. The discussion dives into timing for treatment escalation, personalizing care based on disease volume, and the use of genomic tools like the Decipher score in decision-making. Dr. McKay also touches on patient quality of life and the importance of integrating complementary strategies.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Defining Doublet vs Triplet Therapy

  • Triplet therapy combines ADT, an AR pathway inhibitor, and chemotherapy (docetaxel).
  • Doublet therapy is ADT plus one additional agent, usually an ARSI.
INSIGHT

No Definitive Data on Doublet vs Triplet

  • We lack level one evidence comparing doublet versus triplet in metastatic hormone-sensitive prostate cancer.
  • Clinical factors currently guide who receives intensified therapy until research provides clearer answers.
ADVICE

Who Benefits from Triplet Therapy?

  • Ideal triplet therapy candidates have high volume or symptomatic disease and good health status.
  • Genomic profiling and disease aggressiveness may also support therapy intensification.
Get the Snipd Podcast app to discover more snips from this episode
Get the app